REGISTER
Prof. Scott T. Tagawa on New Insights from ASCO GU 2026
Prof. Tagawa shares key insights from ASCO GU 2026, highlighting how the combination of enzalutamide and radium-223 in the PEACE-3 study may reshape the first-line treatment landscape for metastatic castration-resistant prostate cancer (mCRPC).

Prof. Scott T. Tagawa, Weill Cornell Medicine, United States

Prof. Tagawa shares key insights from ASCO GU 2026, highlighting how the combination of enzalutamide and radium-223 in the PEACE-3 study may reshape the first-line treatment landscape for metastatic castration-resistant prostate cancer (mCRPC). He also discusses the broader implications for precision treatment strategies and the evolving future of prostate cancer care.

Watch the full interview for comprehensive expert perspectives.

0
0
Loading